Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• Study assessing FNAIT risk across ethnicities to begin soon

  A prospective study aiming to analyze the risk of FNAIT among different ethnic groups is expected to begin soon.

• Review: How nipocalimab works to prevent FNAIT

  The molecular properties of nipocalimab determine its ability for preventing FNAIT without compromising other immune functions.

• Neonatal IVH most frequently occurs six hours after birth

  Neonatal intraventricular hemorrhage, a potential FNAIT complication, is most frequent six hours after birth in preterm infants.

• Rallybio’s potential FNAIT treatment enters Phase II

  A new Phase II clinical trial investigating the experimental RLY212 in pregnant patients at risk of FNAIT has recently begun.

• J&J’s nipocalimab trial for FNAIT set to begin phase 3

  A Phase 3 clinical trial aiming to assess the safety and efficacy of nipocalimab in pregnancies at risk of FNAIT is set to begin soon.

• Rallybio’s novel therapy successfully prevents FNAIT in mice

  In a recent study, Rallybio’s new therapy, RLYB212, successfully prevented fetal and neonatal alloimmune thrombocytopenia in mice.

• Characteristics of prenatal intracranial hemorrhage due to FNAIT

  The distinct patterns of perinatal intracranial hemorrhage (pIH), a feared FNAIT complication, were detailed in a recent study.

• Europe greenlights experimental FNAIT therapy for further trials

  A Phase 2 clinical trial for an experimental treatment for FNAIT was recently approved by the European Medicines Agency.

• Donor characteristics may affect quality of FNAIT transfusions

  A recent study showed donor characteristics can affect the quantity of platelets obtained for FNAIT platelet transfusions.

• Potential therapeutic alternative for FNAIT shows early promise

  Researchers have successfully synthesized an antibody against the CD36 platelet antigen, which has potential therapeutic implications for FNAIT.